Abstract: The present invention relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody for treating abnormal cell growth (e.g., cancer).

Abstract: The present invention relates, in part, to methods, compounds, and compositions of a KRAS G12D inhibitor in combination with a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).

Abstract: The present disclosure provides, in part, combinations (e.g., combinations of compounds as described herein, e.g., a dual RAF/MEK inhibitor and a DDR pathway inhibitor), which can be used, for example, in methods of treating abnormal cell growth (e.g., cancer) in a subject in need thereof. Provided herein is a method of treating a cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a dual RAF/MEK inhibitor and an effective amount of a DDR pathway inhibitor.

Abstract: The present invention relates, in part, to methods, compounds, and compositions of an autophagy pathway inhibitor in combination with a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).

Abstract: The present disclosure relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor, in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody, and a KRAS G12C inhibitor, and optionally a FAK inhibitor, for treating abnormal cell growth (e.g., cancer).

Abstract: Combinations of compounds as described herein, a BRAF V600 inhibitor, a pan-RAF inhibitor, a CRAF inhibitor, or a RAF inhibitor, and a dual RAF/MEK inhibitor, can be used, for example, in methods of treating abnormal cell growth/cancers in a subject in need thereof.

Abstract: The present disclosure provides, in part, methods of reducing the severity of or preventing toxicity or an adverse event associated with administration of a dual RAF/MEK inhibitor in a subject, comprising administering to the subject an effective amount of the dual RAF/MEK inhibitor, an effective amount of an antibiotic agent, and optionally an effective amount of a corticosteroid.

Abstract: The present invention relates to methods, compositions, and oral dosage forms of a SHP2 inhibitor, a SOS1 inhibitor, an ERK1/2 inhibitor, a CDK4/6 inhibitor, an AKT inhibitor, an mTOR inhibitor, a pan-HER inhibitor, or an EGFR inhibitor in combination with a MEK inhibitor or a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).

Abstract: The present invention relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody for treating abnormal cell growth (e.g., cancer).

Abstract: The present invention relates to methods, compositions, and oral dosage forms of a KRAS G12C inhibitor in combination with a FAK inhibitor and/or a MEK. inhibitor or a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).

Abstract: The present disclosure relates generally to methods of making immune effector cells, such as those engineered to express a Chimeric Antigen Receptor (CAR) including CAR-T cells, and compositions comprising the same, for use in treating cancer.